Potential serum biomarkers in bladder cancer by nuclear magnetic resonance (NMR) spectroscopy

Ergun B., İnce Ü., Sağlıcan Y., Argun Ö. B., Serdar M. A., Kural A. R., ...Daha Fazla

FEBS Open Bio, İstanbul, Türkiye, 5 - 09 Temmuz 2025, cilt.15, ss.398, (Özet Bildiri)

  • Yayın Türü: Bildiri / Özet Bildiri
  • Cilt numarası: 15
  • Doi Numarası: 10.1002/2211-5463.700711
  • Basıldığı Şehir: İstanbul
  • Basıldığı Ülke: Türkiye
  • Sayfa Sayıları: ss.398
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Bladder cancer (BC) is a widespread and vital disease, with 573

278 new diagnoses worldwide. The gold standard methods for

diagnosing BC are urine cytology and cystoscopy. The

cytopathology of urine specimens is a widely used non-invasive

test for detection. Since cytology has low sensitivity, limiting its

use in low-grade BC, new molecular-based tests are needed for

the early diagnosis of recurrence in patients. In the literature,

there are limited studies focused on non-muscle invasive bladder

cancer (NMIBC) that investigate biomarker discovery and

enhance our understanding of tumor progression. This study

examined serum metabolites in NMIBC patients and controls to

differentiate cancer progression and reveal the underlying

mechanisms of bladder cancer. 100 serum samples (n=50 cancer,

n=50 control) were analyzed using a 600 MHz IVDr nuclear

magnetic resonance (NMR) spectrometry (Bruker BioSpin

GmbH, Germany). Statistical analysis of the metabolites was

performed using MetaboAnalyst 6.0. An orthogonal partial least

squares discriminant analysis (OPLS-DA) model was employed

to distinguish between NMIBC patients and controls. For

pathway analysis, the KEGG metabolic pathway database was

used. To investigate potential changes in the serum metabolic

profile associated with cancer, NMIBC patients were compared

to controls. In the serum samples from NMIBC patients, the

levels of choline, alanine, histidine, leucine, tyrosine, glutamine,

glycine, glutamate, and threonine metabolites were altered with

cancer progression. The identified metabolites were especially

associated with amino acid and fatty acid metabolism. The

results indicate that specific serum metabolites can function as

early-stage-based biomarkers in BC and provide new insights

into the mechanisms underlying NMIBC. However, further

studies are needed to explore their usability as potential

biomarkers for the early diagnosis of patients with NMIBC.